Lung Neoplasm

In this open-label, randomised, phase 3 trial at 22 centres in China, patients with stage IIIB or IV NSCLC who had exon 19 deletion or exon 21 L858R point mutation, and who had not received previous s… (full text at CIViC)

PMID 21783417 · Zhou et al., 2011 · Open in CIViC

In a phase II trial for Bronchioloalveolar carcinoma (BAC, or in situ pulmonary adenocarcinoma), EGFR exons 18-24 were analyzed in 7 patients who had shown a partial response to Erlotinib, and 10 pati… (full text at CIViC)

PMID 15329413 · Pao et al., 2004 · Open in CIViC

In advanced-stage (IIIB or IV) non-small cell lung cancer patients treated with erlotinib, patients whose tumors harbored EGFR mutations (n=3) had a higher 12-week progression-free survival rate compa… (full text at CIViC)

PMID 22025157 · Ramalingam et al., 2011 · Open in CIViC

In the placebo-controlled Phase III study SATURN, using erlotinib maintenance therapy for patients with advanced NSCLC who were selected for response or stable disease after first line chemotherapy, E… (full text at CIViC)

PMID 21969500 · Brugger et al., 2011 · Open in CIViC

This open label Phase 3 Trial performed across 36 centers in Japan (WJTOG3405) assessed patients with postoperative recurrent or stage IIIB/IV NSCLC and activating EGFR mutations (Exon 19 deletion and… (full text at CIViC)

PMID 20022809 · Mitsudomi et al., 2010 · Open in CIViC

In a phase 3 clinical trial of East Asian advanced pulmonary adenocarcinoma patients, a subset of patients with EGFR mutations (n=261) treated with gefitinib were associated with improved response (HR… (full text at CIViC)

PMID 19692680 · Mok et al., 2009 · Open in CIViC

Mutational profiling was performed on EGFR exons 18-24 from a group of 10 retrospectively chosen patients who had shown partial response or clinical imporvement in response to gefitinib, and in 8 pati… (full text at CIViC)

PMID 15329413 · Pao et al., 2004 · Open in CIViC

In a phase 3 clinical trial of non-small cell lung cancer (NSCLC) patients, a subset of patients with EGFR mutations (n=44) treated with gefitinib were associated with improved progression free surviv… (full text at CIViC)

PMID 20038723 · Douillard et al., 2010 · Open in CIViC

In a study of 52 patients with recurrent lung cancer, 27 individuals had EGFR mutation including 2 point mutations in exon 18 (G719A and G1719C), 23 deletions in exon 19, two insertions in exon 19 (I7… (full text at CIViC)

PMID 17409929 · Endoh et al., 2006 · Open in CIViC

In a Japanese phase III study, lung adenocarcinoma patients with one or more of any mutation in their EGFR gene were treated with either Erlotinib or Gefitinib EGFR tyrosine kinase inhibitors to demon… (full text at CIViC)

PMID 27022112 · Urata et al., 2016 · Open in CIViC

Three major drug resistance mutations, namely L718Q, L844V, and C797S were identified in EGFR and caused resistance to both WZ4002 and CO-1686. In contrast, only EGFR C797S caused AZD9291 resistance.… (full text at CIViC)

PMID 25948633 · Ercan et al., 2015 · Open in CIViC

In a retrospective study, 166 non-small cell lung cancer (NSCLC) patients that tended to have selected characteristics known to be predictive for TKI sensitivity (i.e. women, never smokers, and patien… (full text at CIViC)

PMID 21258250 · Ludovini et al., 2011 · Open in CIViC

In this trial, 139 patients with lung adenocarcinomas harbouring EGFR activating mutations were randomly assigned to two groups to receive either EGFR-TKIs alone (n = 70) or a combination of TGFR-TKIs… (full text at CIViC)

PMID 31486833 · Arrieta et al., 2019 · Open in CIViC

A phase 2 study was conducted to compare treatment with pemetrexed and gefinitib (P+G) versus gefinitib monotherapy for a population of 195 East Asian non-squamous NSCLC patients with EGFR mutations (… (full text at CIViC)

PMID 31605797 · Yang et al., 2020 · Open in CIViC

In the randomized, double-blind phase III ORIENT-31 trial, patients with EGFR-mutated, nonsquamous non-small-cell lung cancer that had progressed following EGFR tyrosine kinase inhibitor therapy were … (full text at CIViC)

PMID 37156249 · Lu et al., 2023 · Open in CIViC

This phase 1b/2, multicentre, randomized clinical trial was conducted on the combination of tepotinib and gefitinib on patients with MET overexpression or MET amplification that showed resistance to E… (full text at CIViC)

PMID 32479794 · Wu et al., 2020 · Open in CIViC

A transposon mutagenesis screen for resistance to a second-generation TKI afatinib was performed in EGFR-TKI sensitive PC9 lung adenocarcinoma cell line that harbours exon 19 EGFR deletion. YES1 was f… (full text at CIViC)

PMID 29875142 · Fan et al., 2018 · Open in CIViC

In an in vitro study, MCF-7 cells expressing the EGFR N771delinsGY (N771GY) mutation demonstrated sensitivity to dacomitinib (PF00299804), with YFP-EGFR-ICD relocation observed at 50 nM. In comparison… (full text at CIViC)

PMID 21132006 · Harada et al., 2011 · Open in CIViC

In a stage III lung adenocarcinoma patient of African-American descent with EGFR N771>GY mutation, EGFR N771>GY was reported to be resistant to erlotinib treatment. The patient was treated with 4 cycl… (full text at CIViC)

PMID 21132006 · Harada et al., 2011 · Open in CIViC

In a multinational open label phase II dose randomized study of sunvozertinib in platinum pretreated advanced NSCLC with EGFR exon 20 insertion mutations (WU-KONG1B, NCT03974022; efficacy n = 85 for 2… (full text at CIViC)

PMID 40923280 · Yang et al., 2025 · Open in CIViC

In a retrospective study of 46 Caucasian, advanced lung adenocarcinoma patients, a patient harboring EGFR N771insVH mutation was associated with resistance to erlotinib treatment. The patient survived… (full text at CIViC)

PMID 27032107 · De Grève et al., 2016 · Open in CIViC

In a retrospective study of 2316 Chinese patients with stage IV non-small cell lung carcinoma, a 69 year old male with the novel EGFR exon 20 insertion N771_P772insL received osimertinib as first-line… (full text at CIViC)

PMID 31208370 · Fang et al., 2019 · Open in CIViC

In an in vitro study, a Ba/F3 cell line expressing EGFR N826S demonstrated reduced sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sen… (full text at CIViC)

PMID 19147750 · Kancha et al., 2009 · Open in CIViC

In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have N826Y mutation, and was treated with the 1st generation TKI gefitinib. The patien… (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have N842S mutation, and was treated with the 1st generation TKI gefitinib. The patien… (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

EGFR overexpression was correlated with longer overall survival in patients with advanced NSCLC treated with first line chemotherapy and cetuximab than those treated with first line chemotherapy alone… (full text at CIViC)

PMID 22056021 · Pirker et al., 2012 · Open in CIViC

In this prospective study in 37 patients of whom 34 were treated with different EGFR inhibitors (gefitinib, erlotinib, afatinib), EGFR mutations and a higher relative expression of EGFR in comparison … (full text at CIViC)

PMID 26439803 · Park et al., 2015 · Open in CIViC

In transduced cos7 cells, P772_H773insH cells showed increased sensitivity to erlotinib in comparison to cells with T790M resistance mutation, but decreased erlotinib sensitivity in comparison to L858… (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

A 79 year old Asian male never smoker with not otherwise specified NSCLC harboring EGFR P772_H773insYNP mutation was given erlotinib as first line treatment, and had progressive disease as best respon… (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

A 57 year old male 10 packyear former smoker with lung adenocarcinoma with EGFR P772_V774insPHV mutation was given erlotinib as first line treatment, and had progressive disease as best response with … (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

In an in vitro study, a MCF-7 cell line expressing EGFR P848L demonstrated reduced sensitivity to erlotinib treatment compared to MCF-7 cells expressing EGFR L858R (a known sensitizing mutation to EGF… (full text at CIViC)

PMID 17877814 · de Gunst et al., 2007 · Open in CIViC

A metastatic lung adenocarcinoma (bone and brain) was diagnosed in a 42-year-old woman (patient 3). The primary adenocarcinoma was found in left lower lobe (LLL). Her initial treatment with whole-brai… (full text at CIViC)

PMID 27102076 · Konduri et al., 2016 · Open in CIViC

In a large retrospective study, EGFR exons 18-21 were assessed using direct sequencing in 753 French NSCLC cases. Clinical details and patient outcomes were taken, including whether the first generati… (full text at CIViC)

PMID 23749122 · Locatelli-Sanchez et al., 2013 · Open in CIViC

In an in vitro study, a Ba/F3 cell line expressing EGFR R776C demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). … (full text at CIViC)

PMID 19147750 · Kancha et al., 2009 · Open in CIViC

EGFR belongs to a family of receptor tyrosine kinases that includes EGFR/erbB-1, Her2/erbB-2, Her3/erbB-3, and Her4/erbB-4. Ligand binding causes receptor homo- or hetero-dimerization, leading to acti… (full text at CIViC)

PMID 20966921 · Pao et al., 2010 · Open in CIViC

EGFR belongs to a family of receptor tyrosine kinases that includes EGFR/erbB-1, Her2/erbB-2, Her3/erbB-3, and Her4/erbB-4.

PMID 15870435 · Cappuzzo et al., 2005 · Open in CIViC

In this systematic pubmed search, EGFR variants associated with Response to EGFR-directed therapy were summarized. One Patient with an EGFR R832L Mutation achieved stable disease with an EGFR Inhibito… (full text at CIViC)

PMID 23344264 · Yeh et al., 2013 · Open in CIViC

106 Chinese patients who received second-line gefitinib were screened for EGFR mutations. One Patient with an EGFR R832L Mutation achieved stable disease. Treatment was ongoing after 7 months at the t… (full text at CIViC)

PMID 19020901 · Xu et al., 2009 · Open in CIViC

A 62 year-old female never smoker diagnosed of lung adenocarcinoma that was negative for EGFR and ALK alterations (EGFR hotspot tissue NGS) was treated with carboplatin/ pemetrexed/ bevacizumab (x 6 c… (full text at CIViC)

PMID 29472054 · Raez et al., 2018 · Open in CIViC

A 48 year old male with lung adenocarcinoma who was a smoker presented with diminished vision and tinnitus, and multiple intracranial brain metastasis were identified by CT. Metastatic site was submit… (full text at CIViC)

PMID 29290255 · Zhu et al., 2018 · Open in CIViC

Response to Afatinib was assessed by measuring viability of Ba/F3 cells expressing the EGFR::RAD51 variant 72 hours after treatment with Afatinib (10-1000 nmol/L). Viability was measured using the Cel… (full text at CIViC)

PMID 27102076 · Konduri et al., 2016 · Open in CIViC

The paper reports three patients (P1, P2 and P4) with Stage IV lung adenocarcinoma with metastasis, harboring the EGFR::RAD51 fusion detected by hybrid capture NGS (FoundationOne). Breakpoints were in… (full text at CIViC)

PMID 27102076 · Konduri et al., 2016 · Open in CIViC